3
Participants
Start Date
September 15, 2021
Primary Completion Date
June 9, 2023
Study Completion Date
December 15, 2023
Autologous genetically modified ADP-A2M4CD8 cells
Infusion of autologous genetically modified ADP-A2M4CD8 on Day 1
Memorial Sloan Kettering Cancer Center, New York
Hospital Universitario 12 de Octubre, Córdoba
Hospital Universitario Madrid Sanchinarro (CIOCC), Madrid
Clinica Universidad de Navarra, Navarro
Hospital Universitario Virgen del Rocio, Seville
Hospital Clinico Universitario de Valencia, Ibáñez
University Of Wisconsin Clinical Science Center, Madison
University of Chicago Medicine, Chicago
Washington University School of Medicine- Siteman Cancer Center, St Louis
OU Health Stephenson Cancer Center, Oklahoma City
University Of Texas, MD Anderson Cancer Center, Houston
City of Hope National Medical Center, Duarte
Providence Cancer Institute Franz Clinic, Portland
Hospital Fundacion Jimenez Diaz, Madrid
Princess Margaret Cancer Centre, Toronto
McGill University Health Centre Glen Site, Montreal
Hospital Universitari Vall d'Hebron, la Vall d'Hebron
Lead Sponsor
Collaborators (1)
ICON plc
INDUSTRY
Adaptimmune
INDUSTRY